Which has better earnings & valuation, TECH or RGEN?

Bio-Techne has higher revenue and earnings than Repligen. Bio-Techne is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Techne $1.22B 9.09 $73.40M $0.69 102.65 Repligen $738.26M 10.88 $48.89M $0.90 158.22

Is TECH or RGEN more profitable?

Bio-Techne has a net margin of 9.05% compared to Repligen's net margin of 6.73%. Bio-Techne's return on equity of 13.57% beat Repligen's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Techne 9.05% 13.57% 10.66% Repligen 6.73% 4.88% 3.48%

Does the media prefer TECH or RGEN?

In the previous week, Bio-Techne had 7 more articles in the media than Repligen. MarketBeat recorded 10 mentions for Bio-Techne and 3 mentions for Repligen. Repligen's average media sentiment score of 0.75 beat Bio-Techne's score of 0.53 indicating that Repligen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RGEN or A?

In the previous week, Agilent Technologies had 4 more articles in the media than Repligen. MarketBeat recorded 7 mentions for Agilent Technologies and 3 mentions for Repligen. Agilent Technologies' average media sentiment score of 1.32 beat Repligen's score of 0.75 indicating that Agilent Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agilent Technologies 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, BIO or RGEN?

Bio-Rad Laboratories has higher revenue and earnings than Repligen. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Rad Laboratories $2.58B 3.07 $759.90M $6.07 48.89 Repligen $738.26M 10.88 $48.89M $0.90 158.22

Does the media refer more to BIO or RGEN?

In the previous week, Repligen had 2 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 3 mentions for Repligen and 1 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 1.34 beat Repligen's score of 0.75 indicating that Bio-Rad Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Rad Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, RGEN or DHR?

Danaher has higher revenue and earnings than Repligen. Danaher is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Repligen $738.26M 10.88 $48.89M $0.90 158.22 Danaher $24.57B 5.70 $3.61B $5.17 38.27

Is RGEN or DHR more profitable?

Danaher has a net margin of 14.89% compared to Repligen's net margin of 6.73%. Danaher's return on equity of 10.91% beat Repligen's return on equity. Company Net Margins Return on Equity Return on Assets Repligen 6.73% 4.88% 3.48% Danaher 14.89% 10.91% 6.94%

Does the media refer more to RGEN or DHR?

In the previous week, Danaher had 12 more articles in the media than Repligen. MarketBeat recorded 15 mentions for Danaher and 3 mentions for Repligen. Danaher's average media sentiment score of 1.03 beat Repligen's score of 0.75 indicating that Danaher is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Danaher 8 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RGEN or MTD?

In the previous week, Mettler-Toledo International had 3 more articles in the media than Repligen. MarketBeat recorded 6 mentions for Mettler-Toledo International and 3 mentions for Repligen. Repligen's average media sentiment score of 0.75 beat Mettler-Toledo International's score of 0.45 indicating that Repligen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mettler-Toledo International 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Repligen (RGEN) Competitors

$142.40 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$143.00 +0.60 (+0.42%)

As of 07/2/2026 05:54 PM Eastern

Compare

RGEN vs. TECH, A, BIO, DHR, and MTD

Should you buy Repligen stock or one of its competitors? MarketBeat compares Repligen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Repligen include Bio-Techne (TECH), Agilent Technologies (A), Bio-Rad Laboratories (BIO), Danaher (DHR), and Mettler-Toledo International (MTD). These companies are all part of the "medical" sector.

How does Repligen compare to Bio-Techne?

Bio-Techne (NASDAQ:TECH) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Bio-Techne has a net margin of 9.05% compared to Repligen's net margin of 6.73%. Bio-Techne's return on equity of 13.57% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	9.05%	13.57%	10.66%
Repligen	6.73%	4.88%	3.48%

Bio-Techne currently has a consensus price target of $67.79, indicating a potential downside of 4.30%. Repligen has a consensus price target of $164.64, indicating a potential upside of 15.62%. Given Repligen's stronger consensus rating and higher probable upside, analysts clearly believe Repligen is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.33
Repligen	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.88

99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by company insiders. Comparatively, 0.6% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bio-Techne has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market. Comparatively, Repligen has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market.

Bio-Techne has higher revenue and earnings than Repligen. Bio-Techne is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.09	$73.40M	$0.69	102.65
Repligen	$738.26M	10.88	$48.89M	$0.90	158.22

In the previous week, Bio-Techne had 7 more articles in the media than Repligen. MarketBeat recorded 10 mentions for Bio-Techne and 3 mentions for Repligen. Repligen's average media sentiment score of 0.75 beat Bio-Techne's score of 0.53 indicating that Repligen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bio-Techne beats Repligen on 9 of the 17 factors compared between the two stocks.

How does Repligen compare to Agilent Technologies?

Repligen (NASDAQ:RGEN) and Agilent Technologies (NYSE:A) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

In the previous week, Agilent Technologies had 4 more articles in the media than Repligen. MarketBeat recorded 7 mentions for Agilent Technologies and 3 mentions for Repligen. Agilent Technologies' average media sentiment score of 1.32 beat Repligen's score of 0.75 indicating that Agilent Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agilent Technologies	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Repligen presently has a consensus price target of $164.64, indicating a potential upside of 15.62%. Agilent Technologies has a consensus price target of $160.88, indicating a potential upside of 23.01%. Given Agilent Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Agilent Technologies is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.88
Agilent Technologies	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

Agilent Technologies has a net margin of 19.55% compared to Repligen's net margin of 6.73%. Agilent Technologies' return on equity of 24.33% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	6.73%	4.88%	3.48%
Agilent Technologies	19.55%	24.33%	12.99%

Repligen has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market.

Agilent Technologies has higher revenue and earnings than Repligen. Agilent Technologies is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$738.26M	10.88	$48.89M	$0.90	158.22
Agilent Technologies	$6.95B	5.32	$1.30B	$4.98	26.26

97.6% of Repligen shares are held by institutional investors. 0.6% of Repligen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Agilent Technologies beats Repligen on 12 of the 16 factors compared between the two stocks.

How does Repligen compare to Bio-Rad Laboratories?

Bio-Rad Laboratories (NYSE:BIO) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, Repligen had 2 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 3 mentions for Repligen and 1 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 1.34 beat Repligen's score of 0.75 indicating that Bio-Rad Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Rad Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Repligen has a net margin of 6.73% compared to Bio-Rad Laboratories' net margin of 6.52%. Repligen's return on equity of 4.88% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	6.52%	3.56%	2.49%
Repligen	6.73%	4.88%	3.48%

Bio-Rad Laboratories has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, Repligen has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

Bio-Rad Laboratories presently has a consensus price target of $303.33, indicating a potential upside of 2.21%. Repligen has a consensus price target of $164.64, indicating a potential upside of 15.62%. Given Repligen's stronger consensus rating and higher possible upside, analysts plainly believe Repligen is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Repligen	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.88

65.2% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 30.3% of Bio-Rad Laboratories shares are owned by company insiders. Comparatively, 0.6% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Bio-Rad Laboratories has higher revenue and earnings than Repligen. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58B	3.07	$759.90M	$6.07	48.89
Repligen	$738.26M	10.88	$48.89M	$0.90	158.22

Summary

Repligen beats Bio-Rad Laboratories on 11 of the 17 factors compared between the two stocks.

How does Repligen compare to Danaher?

Repligen (NASDAQ:RGEN) and Danaher (NYSE:DHR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

Repligen has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Danaher has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

Danaher has higher revenue and earnings than Repligen. Danaher is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$738.26M	10.88	$48.89M	$0.90	158.22
Danaher	$24.57B	5.70	$3.61B	$5.17	38.27

97.6% of Repligen shares are owned by institutional investors. Comparatively, 79.1% of Danaher shares are owned by institutional investors. 0.6% of Repligen shares are owned by company insiders. Comparatively, 10.8% of Danaher shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Danaher had 12 more articles in the media than Repligen. MarketBeat recorded 15 mentions for Danaher and 3 mentions for Repligen. Danaher's average media sentiment score of 1.03 beat Repligen's score of 0.75 indicating that Danaher is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Danaher	8 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Danaher has a net margin of 14.89% compared to Repligen's net margin of 6.73%. Danaher's return on equity of 10.91% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	6.73%	4.88%	3.48%
Danaher	14.89%	10.91%	6.94%

Repligen presently has a consensus price target of $164.64, indicating a potential upside of 15.62%. Danaher has a consensus price target of $233.61, indicating a potential upside of 18.08%. Given Danaher's higher possible upside, analysts plainly believe Danaher is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.88
Danaher	1 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Danaher beats Repligen on 11 of the 17 factors compared between the two stocks.

How does Repligen compare to Mettler-Toledo International?

Repligen (NASDAQ:RGEN) and Mettler-Toledo International (NYSE:MTD) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Repligen currently has a consensus target price of $164.64, suggesting a potential upside of 15.62%. Mettler-Toledo International has a consensus target price of $1,408.55, suggesting a potential upside of 7.69%. Given Repligen's stronger consensus rating and higher probable upside, equities analysts plainly believe Repligen is more favorable than Mettler-Toledo International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.88
Mettler-Toledo International	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46

Mettler-Toledo International has higher revenue and earnings than Repligen. Mettler-Toledo International is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$738.26M	10.88	$48.89M	$0.90	158.22
Mettler-Toledo International	$4.03B	6.56	$869.19M	$42.64	30.67

In the previous week, Mettler-Toledo International had 3 more articles in the media than Repligen. MarketBeat recorded 6 mentions for Mettler-Toledo International and 3 mentions for Repligen. Repligen's average media sentiment score of 0.75 beat Mettler-Toledo International's score of 0.45 indicating that Repligen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mettler-Toledo International	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.6% of Repligen shares are owned by institutional investors. Comparatively, 95.1% of Mettler-Toledo International shares are owned by institutional investors. 0.6% of Repligen shares are owned by company insiders. Comparatively, 0.7% of Mettler-Toledo International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Repligen has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, Mettler-Toledo International has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

Mettler-Toledo International has a net margin of 21.40% compared to Repligen's net margin of 6.73%. Repligen's return on equity of 4.88% beat Mettler-Toledo International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	6.73%	4.88%	3.48%
Mettler-Toledo International	21.40%	-622.80%	24.97%

Summary

Repligen beats Mettler-Toledo International on 9 of the 17 factors compared between the two stocks.

Get Repligen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RGEN vs. The Competition

Export

Metric	Repligen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.03B	$3.78B	$7.19B	$12.47B
Dividend Yield	N/A	2.16%	2.67%	6.51%
P/E Ratio	158.22	21.43	27.99	24.69
Price / Sales	10.88	325.99	535.28	98.66
Price / Cash	41.68	147.12	49.26	57.09
Price / Book	3.81	8.66	10.96	6.46
Net Income	$48.89M	$23.81M	$3.57B	$337.01M
7 Day Performance	-3.14%	3.39%	2.12%	1.69%
1 Month Performance	12.52%	6.15%	2.80%	0.67%
1 Year Performance	11.81%	62.61%	33.40%	23.93%

Repligen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RGEN Repligen	3.6053 of 5 stars	$142.40 flat	$164.64 +15.6%	+11.8%	$8.03B	$738.26M	158.22	2,000
TECH Bio-Techne	1.7781 of 5 stars	$70.90 -0.1%	$68.29 -3.7%	+33.3%	$11.12B	$1.22B	102.76	3,100	Analyst Downgrade High Trading Volume
A Agilent Technologies	4.9097 of 5 stars	$132.97 -2.2%	$160.88 +21.0%	+7.9%	$38.41B	$7.23B	26.70	18,100	Positive News Ex-Dividend Gap Up
BIO Bio-Rad Laboratories	1.0479 of 5 stars	$295.04 -1.9%	$303.33 +2.8%	+18.0%	$8.05B	$2.58B	48.61	7,450	News Coverage Positive News
DHR Danaher	4.5233 of 5 stars	$193.05 -1.6%	$233.61 +21.0%	-2.6%	$138.86B	$24.57B	37.34	60,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RGEN) was last updated on 7/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Repligen (RGEN) Competitors

RGEN vs. TECH, A, BIO, DHR, and MTD

How does Repligen compare to Bio-Techne?

Summary

How does Repligen compare to Agilent Technologies?

Summary

How does Repligen compare to Bio-Rad Laboratories?

Summary

How does Repligen compare to Danaher?

Summary

How does Repligen compare to Mettler-Toledo International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGEN vs. The Competition

Repligen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Repligen (RGEN) Competitors

RGEN vs. TECH, A, BIO, DHR, and MTD

How does Repligen compare to Bio-Techne?

Is TECH or RGEN more profitable?

Do analysts recommend TECH or RGEN?

Do insiders & institutionals believe in TECH or RGEN?

Which has more volatility & risk, TECH or RGEN?

Which has better earnings & valuation, TECH or RGEN?

Does the media prefer TECH or RGEN?

Summary

How does Repligen compare to Agilent Technologies?

Does the media favor RGEN or A?

Do analysts prefer RGEN or A?

Is RGEN or A more profitable?

Which has more volatility & risk, RGEN or A?

Which has stronger earnings & valuation, RGEN or A?

Do institutionals & insiders believe in RGEN or A?

Summary

How does Repligen compare to Bio-Rad Laboratories?

Does the media refer more to BIO or RGEN?

Is BIO or RGEN more profitable?

Which has more risk and volatility, BIO or RGEN?

Do analysts prefer BIO or RGEN?

Do insiders & institutionals hold more shares of BIO or RGEN?

Which has preferable earnings & valuation, BIO or RGEN?

Summary

How does Repligen compare to Danaher?

Which has more risk and volatility, RGEN or DHR?

Which has stronger valuation & earnings, RGEN or DHR?

Do insiders and institutionals have more ownership in RGEN or DHR?

Does the media refer more to RGEN or DHR?

Is RGEN or DHR more profitable?

Do analysts recommend RGEN or DHR?

Summary

How does Repligen compare to Mettler-Toledo International?

Do analysts recommend RGEN or MTD?

Which has higher valuation and earnings, RGEN or MTD?

Does the media favor RGEN or MTD?

Do institutionals & insiders have more ownership in RGEN or MTD?

Which has more volatility and risk, RGEN or MTD?

Is RGEN or MTD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGEN vs. The Competition

Repligen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools